Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients.

[1]  F. Crea,et al.  Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations , 2021, Expert review of clinical pharmacology.

[2]  I. Porto,et al.  Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis , 2021, The Lancet.

[3]  K. Bailey,et al.  Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. , 2020, JAMA.

[4]  A. Almeman.  Major CYP450 polymorphism Among Saudi Patients. , 2020, Drug metabolism letters.

[5]  James R. Ashenhurst,et al.  CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System , 2020, Clinical and translational science.

[6]  F. Asselbergs,et al.  Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy , 2020, BMC Cardiovascular Disorders.

[7]  J. Cigarroa,et al.  Genotype-Guided Strategy for P2Y12 Inhibitors in Coronary Artery Disease: A Meta-Analysis of Randomized Clinical Trials. , 2020, JACC. Cardiovascular interventions.

[8]  M. Postma,et al.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.

[9]  Marco Valgimigli,et al.  Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. , 2019, JACC. Cardiovascular interventions.

[10]  V. Lauschke,et al.  Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe , 2019, European Journal of Human Genetics.

[11]  Saleh Alghamdi,et al.  The first survey of the Saudi Acute Myocardial Infarction Registry Program: Main results and long-term outcomes (STARS-1 Program) , 2019, PloS one.

[12]  G. Stouffer,et al.  Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[13]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[14]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[15]  M. Al-Dosari,et al.  CYP2C19 Genetic Polymorphism in Saudi Arabians , 2013, Basic & clinical pharmacology & toxicology.

[16]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[17]  M. Al-Omran.  Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action , 2012, Vascular health and risk management.

[18]  G. Mancia,et al.  Coronary artery disease in Africa and the Middle East , 2012, Therapeutics and clinical risk management.

[19]  S. Heptinstall,et al.  Anti-platelet therapy: ADP receptor antagonists , 2011, British journal of clinical pharmacology.

[20]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[21]  M. Zubaid,et al.  Prevalence and Impact of Cardiovascular Risk Factors Among Patients Presenting With Acute Coronary Syndrome in the Middle East , 2011, Clinical cardiology.

[22]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[23]  V. Deneer,et al.  Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.

[24]  Osamu Okazaki,et al.  Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite , 2010, Drug Metabolism and Disposition.

[25]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[26]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[27]  L. Green,et al.  ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction. , 2009, American family physician.

[28]  Jessica L Mega,et al.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2009, Circulation.

[29]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[30]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[31]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[32]  S. Werns.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2010 .

[33]  E. Antman,et al.  Cytochrome P 450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic , Pharmacodynamic , and Clinical Outcomes , 2009 .